|
Community-based Smoking Cessation Treatment for Adults With High Stress Sensitivity.
RECRUITINGPhase 3Sponsored by Jasper A. Smits
Actively Recruiting
PhasePhase 3
SponsorJasper A. Smits
Started2023-12-27
Est. completion2027-06-30
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT06053567
Summary
Anxiety sensitivity, reflecting the fear of bodily sensations, is a risk factor for the maintenance and relapse of smoking. This study is designed to address the question - is a smoking cessation intervention personalized to high anxiety sensitive smokers and adapted for implementation by the YMCA effective among racially/ethnically diverse samples?
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Adult (age ≥ 18); * High Anxiety Sensitivity (≥5 on the Short Scale Anxiety Sensitivity Index \[SSASI\]); * Daily smoker, ≥5 cigarettes (including e-cigarettes, little cigars/cigarillos) for ≥1 year; * Motivated to quit smoking as evidenced by a score of ≥5 on a 0-10 Likert scale; * Body mass index \<40; * Medical clearance to participate. * Located near a participating YMCA site (within 50 miles) Exclusion Criteria: * Regular exercise defined as engaging in vigorous-intensity exercise for at least 75 minutes per week for the last 3 months * Receiving current intervention for smoking cessation. * Outstanding debt to the YMCA * Listed as a sex offender on the National Sex Offender Registry
Conditions2
AnxietyNicotine Dependence
Locations1 site
University of Texas at Austin
Austin, Texas, 78712
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 3
SponsorJasper A. Smits
Started2023-12-27
Est. completion2027-06-30
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT06053567